China NT Pharma Group Company Limited (1011.HK)
HKD 0.41
(-7.87%)
HKD 0.41
(-7.87%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.6 Million CNY | 677.54% |
| 2022 | 463 Thousand CNY | -99.78% |
| 2021 | 213.68 Million CNY | 310.52% |
| 2020 | 52.05 Million CNY | -23.45% |
| 2019 | 67.99 Million CNY | 1815.27% |
| 2018 | 3.55 Million CNY | 0.0% |
| 2017 | - CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| 2015 | - CNY | -100.0% |
| 2014 | 120 Million CNY | -61.28% |
| 2013 | 309.94 Million CNY | 1449.71% |
| 2012 | 20 Million CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| 2010 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 3.25 Million CNY | 0.0% |
| 2023 Q2 | 3.76 Million CNY | 0.0% |
| 2023 FY | 3.6 Million CNY | 677.54% |
| 2023 Q4 | 3.6 Million CNY | 0.0% |
| 2022 Q2 | 211.43 Million CNY | 0.0% |
| 2022 FY | 463 Thousand CNY | -99.78% |
| 2022 Q4 | 463 Thousand CNY | 0.0% |
| 2021 Q2 | 49.44 Million CNY | 0.0% |
| 2021 Q4 | 213.68 Million CNY | 0.0% |
| 2021 FY | 213.68 Million CNY | 310.52% |
| 2020 FY | 52.05 Million CNY | -23.45% |
| 2020 Q2 | 71.17 Million CNY | 0.0% |
| 2020 Q4 | 52.05 Million CNY | 0.0% |
| 2019 Q2 | 54.29 Million CNY | 0.0% |
| 2019 FY | 67.99 Million CNY | 1815.27% |
| 2019 Q4 | 67.99 Million CNY | 0.0% |
| 2018 Q2 | 96.58 Million CNY | 0.0% |
| 2018 FY | 3.55 Million CNY | 0.0% |
| 2018 Q4 | 3.55 Million CNY | 0.0% |
| 2017 FY | - CNY | 0.0% |
| 2017 Q2 | 132.49 Million CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 Q2 | 57 Million CNY | 0.0% |
| 2015 Q4 | - CNY | 0.0% |
| 2015 FY | - CNY | -100.0% |
| 2015 Q2 | -22.21 Million CNY | 0.0% |
| 2014 Q4 | 120 Million CNY | 0.0% |
| 2014 Q2 | 434.52 Million CNY | 0.0% |
| 2014 FY | 120 Million CNY | -61.28% |
| 2013 Q4 | 309.94 Million CNY | 0.0% |
| 2013 FY | 309.94 Million CNY | 1449.71% |
| 2013 Q2 | 313.25 Million CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 Q4 | 20 Million CNY | 0.0% |
| 2012 FY | 20 Million CNY | 0.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| 2010 Q4 | - CNY | 0.0% |
| 2010 FY | - CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | -73.661% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | 99.636% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | 96.926% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | 98.697% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | 94.903% |
| Essex Bio-Technology Limited | 36.05 Million HKD | 90.016% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | 71.877% |
| PuraPharm Corporation Limited | 81.09 Million HKD | 95.561% |
| SSY Group Limited | 1.94 Billion HKD | 99.815% |
| JBM (Healthcare) Limited | 43.8 Million HKD | 91.781% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | 99.392% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 99.978% |